The Next New Thing

By Sarah Greene The Next New Thing Our conversation is about to get a lot more interesting. Can we invigorate science through greater interactive behavior? Way before Facebook, scientists and readers of science—pioneers by nature—were establishing their own brand of participatory media. Twenty-two years ago, when Fred Ausubel and colleagues at Massachusetts General Hospital and Harvard Medical School were formulating the lab manual Curr

Written bySarah Greene
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Way before Facebook, scientists and readers of science—pioneers by nature—were establishing their own brand of participatory media. Twenty-two years ago, when Fred Ausubel and colleagues at Massachusetts General Hospital and Harvard Medical School were formulating the lab manual Current Protocols in Molecular Biology with me, we knew its success hinged on constant correction, updating, and improvement. The publishing process had to mirror the process of experimentation. Freud’s (not Fred’s) dictum, “from error to error, one discovers the truth” was our mantra, and we recognized that traditional print media could not accommodate the accelerating pace of change in methodologies. In those pre–World Wide Web days, we developed quarterly protocol updates, with our own web of reader feedback: postage-paid response cards tucked into every supplement, encouraging researchers to send in corrections and ideas for improvement.

Dry Out, Put Away

Pharma on Facebook?

The Future of Public Engagement

What would induce the busy ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies